Revolutionary medical treatments offer new hope for chronic pain sufferers through advanced technology, targeted medications ...

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...

The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

Experts with the Cleveland Clinic say the drug has a lot of potential, especially since it is considered nonaddictive.

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...

On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...